Cystic Fibrosis

Curious how 2025’s EMA decisions will change the healthcare landscape? 🔬 The EMA recommended 104 medicines—including 38 new active substances, a record 41 biosimilars, and 16 orphan drugs—while expanding global reach through EU‑M4All, signaling major shifts in access, safety monitoring, and cost dynamics. These trends matter for HEOR, pricing and reimbursement strategies as biosimilars ease budgets and ATMPs demand real‑world evidence for value cases. Read the full analysis to explore implications for market access, HTA and clinical strategy. #SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #innovation

💊 How can access to essential medications change lives? Our latest article looks into the significant strides made in South Africa regarding access to Trikafta for cystic fibrosis patients. Thanks to the initiatives by Vertex Pharmaceuticals reviewed by the Competition Commission, many patients can now obtain this critical medication more affordably. This is an important advancement in ensuring equitable healthcare access. Read more about how these efforts are enhancing patient accessibility and the impact of Section 21 authorizations! #SyenzaNews #pharmaceuticals #MarketAccess #HealthcareInnovation